Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy

AIM: ). METHODS: -positive patients with associated gastrointestinal diseases from April 2014 to December 2015 at Hattori Clinic, Japan. The primary endpoint was the eradication rate, which was assessed with a full analysis set. The secondary endpoints were adverse events and related factors. RESULTS: = 0.054), although the vonoprazan group exhibited a wider range of adverse events. Vonoprazan-based triple therapy was highly effective as a second-line treatment, with an eradication rate similar to that of PPI-based therapy. CONCLUSION: therapy, particularly for smokers. However, caution is required due to possible adverse events.